StockUS listing USFTRENASDAQHealthcareEarnings Deterioration

Fortrea Holdings Inc.(FTRE) Stock Analysis | Healthcare

USD --+0.00%
Reward52Moderate
Risk76High
75%Data
Thin -3% profit margin
USD —+0.00 (+0.00%) Previous close · NASDAQ
Market cap 1.79Bn
Reward Ratingⓘ52 Moderate reward assessment · 75% data coverage
Bottom 50% of stocksView factors
Risk Ratingⓘ76 High risk assessment
Risk factors availableUnlock details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on FTRE to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is Fortrea Holdings Inc.?

, a contract research organization, provides biopharmaceutical product and medical device development solutions to pharmaceutical, biotechnology, and medical device customers worldwide.

AI Brief Pro

The brief on Fortrea Holdings Inc.

The story behind the price, the case for and against, and what could go wrong. Open a part to read it.

What is Fortrea Holdings Inc.?

, a contract research organization, provides biopharmaceutical product and medical device development solutions to pharmaceutical, biotechnology, and medical device customers worldwide. It offers clinical pharmacology, such as clinical research units, external partnerships, project management, study design and monitoring, bioanalytics and biomarkers, pharmacokinetics, modeling and simulation, and biometrics; and clinical development, including phase I through IV clinical and real-world evidence studies, regulatory affairs, protocol design, operational planning, study and site start-up, patient recruitment, project management, comprehensive site and medical monitoring, data management and biostatistics, pharmacovigilance, medical writing, and mobile clinical services. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 1.79B.

Financial Highlights

Investment Breakdown

Growth
Moderate growth momentum — positive trajectory without breakout acceleration.
Profitability
Thin or inconsistent margins weigh on earnings quality.
Risk
Elevated volatility implies higher downside and expectation risk.
Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Moderate (52)
Company Information
SectorHealthcare
IndustryBiotechnology
Beta1.863
Insider Activity
12M windowBearish
Shares soldShares bought
0-3months
23,395 shares
$57k
0
3-6months
9240,724 shares
$4.4M
0
6-9months
917,195 shares
$165k
0
9-12months
0
0